Calypte!!! Was seht Ihr als ... Fortsetzung
Seite 15 von 52 Neuester Beitrag: 18.11.03 22:12 | ||||
| Eröffnet am: | 06.10.03 09:50 | von: Kalli2003 | Anzahl Beiträge: | 2.29 |
| Neuester Beitrag: | 18.11.03 22:12 | von: Moneyworks | Leser gesamt: | 62.240 |
| Forum: | Hot-Stocks | Leser heute: | 19 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 12 | 13 | 14 | | 16 | 17 | 18 | ... 52 > | ||||
Mo Di ruhiger Mi die 1.40 antesten ...
ich bin mittlerweile einfach auf "hold" - dat wird
Das ändert doch nichts an der Tatsache das Marr noch
teurer eingekauft hat.
Der Kurs wird schon steigen, wahrscheinlich wenn der grösste
Teil der Aktien in festen Händen ist.
seht euch das mal an :
 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gruss sam
Sieht recht interessant aus, obwohl die Umsätze in USA (noch) recht dürftig sind.
Grüße von ZN
HIV/AIDS Becoming Young Person's Disease
Wed Oct 8,11:05 PM ET Add Health - AP to My Yahoo!
By JANE WARDELL, Associated Press Writer
LONDON - Young people are increasingly responsible for the spread of HIV (news - web sites)/AIDS (news - web sites) around the world because of poverty and a severe lack of information and prevention services, the United Nations (news - web sites) said Wednesday.
AP Photo
In Yahoo! Health
Heartburn
Is it GERD?
--------------------------------------------------
More from Yahoo! Health:
• Check your symptoms
• How is it diagnosed?
• Learn about treatment
Every 14 seconds a person between 15 and 24 is infected with the virus. They now account for half all new cases of the disease, the U.N. Population Fund said in its annual State of the World's Population report.
"We will have a global catastrophe if we ignore young people and ignore their needs," said Thoraya Obaid, the agency's executive director, told a news conference in London.
The "Making 1 Billion Count" report cautions that there is now the biggest generation of adolescents in history — 1.2 billion of the world's 6.3 billion population are between 10 and 19 — and many are facing deadly diseases, unwanted pregnancy and poverty.
HIV/AIDS has emerged as one of the greatest threats. Aside from the high infection rate, the epidemic also has orphaned 13 million children under age 15, the report said.
If those trends continue, the next generation of adults will face greater poverty and stunted economic progress, the report said.
The report estimates the economic benefit of a single averted HIV/AIDS infection is $34,600 for a poor country — and the social benefits are even greater.
It called for more investment in youth-friendly services, family planning and education programs to help young people with reproductive health issues.
"This is a huge opportunity. It is a one-time opportunity that will not occur again," said Alex Marshall, an author of the report.
Poverty is a factor in the spread of HIV, the report said, because some poor girls exchange sex for money for school fees or to help their families, placing them at risk of infection.
Discussing sexual behavior is taboo in many countries, so many young people do not know how to protect themselves. In Somalia, the report says, just 26 percent of adolescent girls have heard of AIDS and only 1 percent know how to protect themselves.
Obaid said she didn't believe educating youngsters about safe sex would make them more sexually active.
"I would like to stress that giving young people this information is safe, it doesn't lead to promiscuous behavior, as some people say," she said. "On the contrary, it empowers young people to take positive action in their lives and may save their lives as well."
Obaid said the U.N. agency's core message was "ABC" — abstaining from sexual activity, being faithful to one partner and the correct use of condoms.
In sub-Saharan Africa, which has the most cases of HIV/AIDS among youths, about 8.6 million have HIV/AIDS — two-thirds of them female. In South Asia, 1.1 millions youths are infected — 62 percent of them female.
The rate of new infections also is growing rapidly in countries like India and Russia, Marshall said.
The U.N. report also said poverty, early marriage, unwanted pregnancy and homelessness were major issues facing the world's adolescents. Half are poor and a quarter live in extreme poverty — less than a dollar a day.
Among the poorest and least-educated populations, early marriage of girls and expectations of early childbearing persist, contributing to high maternal mortality and reducing girls' chances for education.
Teenage mothers are twice as likely to die in childbirth as women in their 20s; girls under 16 are five times more likely to die than women in their 20s, and 14 million young mothers aged 15-19 give birth each year. About 5 million girls between 15 and 19 undergo unsafe abortion every year, the report said.
Der erste grossangelegte test (wie ich schon am freitag sagte) ist jetzt mit super resultaten abgeschlossen. Caly steht nix mehr im weg. Ich erwarte mir bis Ende nächster Woche ohne neue news Kurse um die 2$, mit news noch am freitag! (bin der meinung das WHO nach china-test entgültig ihre empfehlung aussprechen wird sowie die ergebnise gecheckt wurden.)
mfg
cash-money
Zur info: war damals zu 0.135$ rein, zu 0.5$ raus,
bei 0.65 wieder rein und bei 1.15$ wieder raus. Hab den ganzen Einsatz + Gewinn gestern wieder bei 1.31$ in caly investiert. Caly nimmt zurzeit etwa 42% meines depot in anspruch.
42.02% caly
6.22% d-telcom :o))
13,83% ivoice
13.52% adcanced optics (adot)
11.69% neomedia (neom)
6.72% SAP
0.24% qbid
5,75% nanophase (nanx)
soviel zu meinen positionen... also nix für schwache nerven :o)
ivoc, adot, neom und sap sind hier jedoch nicht langfristig eingeplant (eher um gewinnmitnahmen einzustecken) und gegebenfalls mit verlust rauszugehen und woanders zu plazieren.
und die Theorien das Marr dann nur wieder raus will halte ich schlicht für Quatsch - die Wissen warum sie das machen ... wenn sie das einigermaßen hinkriegen, will von denen keiner seine Aktien für 0,70$ verkaufen
Optionen
| Boardmail an "Realer" |
Wertpapier: Calypte Biomedical |
09 Oct 2003, 08:32 AM EDT
Msg. 20357 of 20360
Jump to msg. #
News!! Order from Bostwana
(COMTEX) B: Calypte Receives Initial Order From Botswana Mistaire LLC Appo
nted Non-Exclusive Distributor For Botswana ( PRNewsw
B: Calypte Receives Initial Order From Botswana Mistaire LLC Appointed Non-Exclu
ive Distributor For Botswana ( PRNewswire-FirstCall )
ALAMEDA, Calif., Oct 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte
Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of
the only two FDA approved HIV-1 antibody tests that can be used on urine
samples, as well as an FDA approved serum HIV-1 antibody Western blot
supplemental test, announced that it has agreed to appoint Mistaire LLC as its
non-exclusive distributor for Botswana.
Mistaire's initial order for 50,000 EIA tests is intended to be used primarily
for evaluations in Botswana prior to registration. In April of 2003, Mistaire
LLC was appointed as Calypte's distributor for the six countries of the Gulf
Cooperative Council.
Tony Cataldo, Calypte's Executive Chairman stated, "We have enjoyed a productive
relationship with Mistaire since appointing them for the GCC, and we know the
company's drive and capabilities. We are happy to extend their territory, and
have every reason to believe that both parties will find this new arrangement
beneficial."
Botswana is a country of just 1.5 million people and is located directly north
of South Africa. Botswana is deeply impacted by the HIV epidemic, and June 2000
statistics compiled by the U.S. Census Bureau, HIV/AIDS Surveillance Data Base
estimate an overall adult HIV prevalence of 36%.
BJ Harid, President of Mistaire said, "Although the country is small, its
struggle with HIV is not. The scope of the HIV problem in Botswana underscores
the need for innovative approaches, and we are pleased to play a role in
bringing the painless and non-invasive urine testing approach to the country."
Calypte Biomedical Corporation headquartered in Alameda, California, is a public
healthcare company dedicated to the development and commercialization of
urine-based diagnostic products and services for Human Immunodeficiency Virus
Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases.
Calypte's tests include the screening EIA and supplemental Western Blot tests,
the only two FDA-approved HIV-1 antibody tests that can be used on urine
samples. The company believes that accurate, non-invasive urine-based testing
methods for HIV and other infectious diseases may make important contributions
to public health by helping to foster an environment in which testing may be
done safely, economically, and painlessly. Calypte markets its products in
countries worldwide through international distributors and strategic partners.
Current product labeling including specific product performance claims can be
found at www.calypte.com.
Statements in this press release that are not historical facts are
forward-looking statements, including statements regarding announcements of
financial results and presentations by the Company. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing that will allow us to continue our
current and future operations and whether demand for our product and testing
service in domestic and international markets will continue to expand. The
Company undertakes no obligation to publicly update these forward-looking
statements to reflect events or circumstances that occur after the date hereof
or to reflect any change in the Company's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact the Company's success are more fully disclosed in the Company's
most recent public filings with the U.S. Securities and Exchange Commission
("SEC"), including its annual report on Form 10-K for the year ended December
31, 2002 and its subsequent filings with the SEC.
Investor Relations Contact:
Tim Clemensen 212-843-9337
tclemensen@rubensteinir.com
SOURCE Calypte Biomedical Corporation
CONTACT: Investor Relations - Tim Clemensen, +1-212-843-9337,
tclemensen@rubensteinir.com
Nix für ungut, aber so'ne Meldung zu bringen ist ja wohl armselig. Demnächst bringen se noch bei jeder Darmverstopfung des VV 'ne Meldung.
Gr., ZN, der die Meldungsflut langsam äußerst kritisch betrachtet...
aber man kann natürlich auch das negativ sehen